Journals / European Journal of Rheumatology / 2018 / Cilt: 5 - Sayı: 3

Catalytic antibodies in patients with systemic lupus erythematosus

Pages
173–178
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The PFR-MCA hydrolysis also appears tobe associated with the active disease (p=0.0988, vs. inactive group).Conclusion: The prevalence of catalytic antibodies represents a general feature of SLE patients, irre-spective of their origin.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Antibodies with catalytic (hydrolytic) properties to DNA or RNA have been reported in sys-temic lupus erythematosus (SLE).
📊
Key Findings & Data:Therefore, we have analyzed the hydrolyzing activity of immunoglob-ulin G (IgG) of SLE patients from the Indian population with an aim to decode whether the catalyticantibody response represents part of an active disease process.Methods: IgGs were isolated from the sera of 72 consecutive patients diagnosed with SLE.
💡
Conclusion & Impact:The PFR-MCA hydrolysis also appears tobe associated with the active disease (p=0.0988, vs. inactive group).Conclusion: The prevalence of catalytic antibodies represents a general feature of SLE patients, irre-spective of their origin.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Antibodies with catalytic (hydrolytic) properties to DNA or RNA have been reported in sys-temic lupus erythematosus (SLE). However, it is well known that ethnicity plays an important role inthe presentation of SLE and severity of the disease; hence, these data may not truly represent a gen-eral feature of all SLE patients. Therefore, we have analyzed the hydrolyzing activity of immunoglob-ulin G (IgG) of SLE patients from the Indian population with an aim to decode whether the catalyticantibody response represents part of an active disease process.Methods: IgGs were isolated from the sera of 72 consecutive patients diagnosed with SLE. As a con-trol, IgGs from healthy donors were used. The catalytic activity of IgG was measured by PFR-MCA andaffinity-linked oligonucleotide nuclease assay.Results: IgGs from patients with SLE from the Indian subcontinent displayed significantly higherhydrolysis rates of both the surrogate substrate, PFR-MCA, and the DNA than IgG from healthy in-dividuals. Intergroup comparisons of the IgG-PFR-MCA interactions with clinical manifestations ofthe disease demonstrated a significantly increased level of hydrolysis among the patients with renalinvolvement who tested positive for anti-dsDNA antibodies. The PFR-MCA hydrolysis also appears tobe associated with the active disease (p=0.0988, vs. inactive group).Conclusion: The prevalence of catalytic antibodies represents a general feature of SLE patients, irre-spective of their origin.

🔖

Cite This Article

GHOSH, K., PRADHAN, V., PANDIT, P., SURVE, P., LECERF, M., RAJADHYAKSHA, A., NADKAR, M., KHADILKAR, P. V., CHOUGULE, D. A., NAIGAONKAR, A. A., DESMAZES, S. L., BAYRY, J., KAVERI, S. V. (2022). Catalytic antibodies in patients with systemic lupus erythematosus. European Journal of Rheumatology, Cilt: 5 - Sayı: 3, 173–178. https://ajindex.com/articles/511665

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Sci- ence 1989; 244: 1158-62. [CrossRef ] Shuster AM, Gololobov GV, Kvashuk OA, Bo- gomolova AE, Smirnov IV, Gabibov AG. DNA hydrolyzing autoantibodies. Science 1992; 256: 665-7. [CrossRef ] Li L, Paul S, Tyutyulkova S, Kazatchkine MD, Ka- veri S. Catalytic activity of anti-thyroglobulin antibodies. J Immunol 1995; 154: 3328-32.
  2. Lacroix-Desmazes S, Bayry J, Misra N, Horn MP, Vil- lard S, Pashov A, et al. The prevalence of proteo- lytic antibodies against factor VIII in hemophilia A. N Engl J Med 2002; 346: 662-7. [CrossRef] Ponomarenko NA, Durova OM, Vorobiev, II, Alek- sandrova ES, Telegin GB, Chamborant OG, et al. Catalytic antibodies in clinical and experimental pathology: human and mouse models. J Immu- nol Methods 2002; 269: 197-211. [CrossRef] Lacroix-Desmazes S, Bayry J, Kaveri SV, Hay- on-Sonsino D, Thorenoor N, Charpentier J, et al. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc Natl Acad Sci U S A 2005; 102: 4109-13. [CrossRef ] Ponomarenko NA, Durova OM, Vorobiev, II, Bel- ogurov AA, Jr, Kurkova IN, Petrenko AG, et al. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A 2006; 103: 281-6. [CrossRef ] Wootla B, Dasgupta S, Dimitrov JD, Bayry J, Levesque H, Borg JY, et al. Factor VIII hydroly- sis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol 2008; 180: 7714-20. [CrossRef ] Belogurov AA, Kurkova IN, Friboulet A, Thomas D, Misikov VK, Zakharova MY, et al. Recognition and degradation of myelin basic protein pep- tides by serum autoantibodies: novel biomark- er for multiple sclerosis. J Immunol 2008; 180: 1258-67. [CrossRef ] Wootla B, Christophe OD, Mahendra A, Dim- itrov JD, Repesse Y, Ollivier V, et al. Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood 2011; 117: 2257-64. [CrossRef ] Hifumi E, Fujimoto N, Arakawa M, Saito E, Mat- sumoto S, Kobayashi N, et al. Biochemical fea- tures of a catalytic antibody light chain, 22F6, prepared from human lymphocytes. J Biol Chem 2013; 288: 19558-68. [CrossRef ] Planque SA, Nishiyama Y, Hara M, Sonoda S, Murphy SK, Watanabe K, et al. Physiological IgM class catalytic antibodies selective for trans- thyretin amyloid. J Biol Chem 2014; 289: 13243- 58. [CrossRef ] Doronin VB, Parkhomenko TA, Castellazzi M, Pa